About Foresite Capital
Foresite Capital is a venture capital firm founded in 2011. It is primarily based out of New York City, United States. As of Mar 2026, Foresite Capital is an active investor, having invested in 211 companies, with 8 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of Pinnacle Medicines Overall, Foresite Capital portfolio has seen 5 unicorns, 80 IPOs and 66 acquisitions including key companies like Hims, Natera and 10X Genomics. A lot of funds co-invest with Foresite Capital, with names like Orbimed sharing a substantial percentage of its portfolio. Foresite Capital has team of 40 people including 12 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series C & 8 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Deals in last 12 months
Foresite Capital's List of Top Investments
Foresite Capital has a portfolio of 211 companies, including 5 unicorns. Their most notable investments are in Element Biosciences and Pharvaris.Their portfolio spans across United States, United Kingdom, Canada and 6 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 7 other sectors, across stages such as Series B, Series C and 8 more. Here is the list of top investments by Foresite Capital:
1. Hims
Online platform offering telehealth services for men's wellness. The company focuses on men's wellness and care, offering treatment options for hair loss, erectile dysfunction, and more.
Key facts about Hims
- Founded Year: 2017
- Location: San Francisco (United States)
- Annual Revenue: $527M as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $197M
- Employee Count: 2,002 as on Mar 31, 2026
- Investors: Disruptive, IVP and 15 Others
- Latest Funding Round: Post IPO, May 08, 2025, $*****
- Highlight: Public
2. Natera
Developer of cell-free DNA testing for oncology, women’s health, and organ health. The test provided by the company inlcude Signatera– a residual disease test (MRD), Altera– tumor genomic profile, Empower– Hereditary cancer test, Prospera Kidney– transplant assessment, Panorama– Noninvasive prenatal testing (NIPT), Anora– Miscarriage Test, and more.
Key facts about Natera
- Founded Year: 2004
- Location: Redwood City (United States)
- Annual Revenue: $2.31B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $152M
- Employee Count: 5,591 as on Mar 31, 2026
- Investors: Harmony Partners, RA Capital Management and 17 Others
- Latest Funding Round: Post IPO, Apr 13, 2020, $*****
- Highlight: Public
3. 10X Genomics
Developer of single-cell, spatial, and in situ tools for high-resolution biological analysis. The company develops instruments, consumables, and software that enable researchers to profile up to a million cells, map RNA and proteins in tissues, and support multiomics workflows, with products cited in publications.
Key facts about 10X Genomics
- Founded Year: 2012
- Location: Pleasanton (United States)
- Annual Revenue: $643M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $243M
- Employee Count: 2,281 as on Mar 31, 2026
- Investors: Meritech, Fidelity Investments and 13 Others
- Latest Funding Round: Series D, Jan 07, 2019, $*****
- Highlight: Public
Global biopharmaceutical company discovering, developing, and delivering innovative medicines. Focused on cutting-edge science and research, the company develops a multitude of treatment modalities. It offers resources for patients, caregivers, and healthcare providers, including medical information, clinical trials, and patient support programs. The company is committed to global inclusion and diversity, making a positive impact on communities worldwide. It fosters partnerships and collaborations to accelerate the development of new medicines. The company focuses on areas such as immunology, oncology, and other serious diseases. It is dedicated to improving patient outcomes and transforming lives through science. The company also provides resources for investors and media, including financial reporting, press releases, and corporate information.
Key facts about Juno Therapeutics
- Founded Year: 2013
- Location: Seattle (United States)
- Annual Revenue: $112M as on Dec 31, 2017
- Stage: Acquired
- Total Funding till date: $317M
- Employee Count: 93 as on Mar 31, 2026
- Investors: RA Capital Management, BB Biotech and 14 Others
- Latest Funding Round: Post IPO, Oct 05, 2017, $*****
- Highlight: Acquired
5. Alector
Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders. The drug candidates include AL001 for dementia, AL101 for neurology, AL002, AL003, AL014 for Alzheimer's, and AL008 for oncology. The company has developed antibody drugs that engage key disease-altering and genetically validated neuro-immune targets.
Key facts about Alector
- Founded Year: 2013
- Location: San Francisco (United States)
- Annual Revenue: $101M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $215M
- Employee Count: 162 as on Mar 31, 2026
- Investors: Amgen Business Development, Deerfield and 20 Others
- Latest Funding Round: Series E, Jul 25, 2018, $*****
- Highlight: Public
Foresite Capital's Year-on-Year Investment Trends
Foresite Capital has invested in 212 companies over the last 14 years, with an average of 9 new investments annually in the last 10 years. In 2025, it made 9 investments, while as of Mar 2026, it has made 5 investments in this year. Its most recent first time investment was in Pinnacle Medicines and most recent follow-on round was in Avenzo Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 5 | 0 | 5 |
2025 | 5 | 4 | 9 |
2024 | 10 | 7 | 17 |
2023 | 3 | 4 | 7 |
2022 | 6 | 8 | 14 |
2021 | 14 | 10 | 24 |
2020 | 21 | 12 | 33 |
2019 | 8 | 6 | 14 |
2018 | 13 | 3 | 16 |
2017 | 5 | 3 | 8 |
Foresite Capital's Investments by Stage
Foresite Capital has made 40 investments in Series B stage with an average round size of $66.3M, 25 investments in Series C stage with an average round size of $118M and 24 investments in Series A stage with an average round size of $87.9M.Stage of entry | No. of Investments |
|---|---|
Series B | 40 |
Series C | 25 |
Series A | 24 |
Post IPO | 9 |
Series D | 8 |
Others | 9 |
Note: We have considered here, only first round of investments
Foresite Capital's Investments by Sector
Foresite Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Sustainability Tech. Notably, it has invested in 188 Tech companies, 183 Enterprise (B2B) companies, 32 Software companies and at least 18 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 96 |
High Tech | 29 |
HealthTech | 17 |
Enterprise Applications | 15 |
Sustainability Tech | 8 |
Others | 21 |
Note: We have considered here, only first round of investments
Foresite Capital's Investments by Geography
Foresite Capital has made most investments in United States (103), followed by United Kingdom where it has made 6 investments.Country | No. of Investments |
|---|---|
United States | 103 |
United Kingdom | 6 |
Ireland | 2 |
China | 1 |
Israel | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Foresite Capital's recent investments
Foresite Capital has made 5 investments in 2026 so far. Pinnacle Medicines and Korsana are the latest among them.Here are the most recent investments by Foresite Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 26, 2026 | - | Series B | 9221 | [+5] | |
Feb 18, 2026 | United States | Series A | 9228 | [+4] | |
Feb 17, 2026 | United States | Series A | 7835 | ||
Feb 03, 2026 | United States | Series D | 5673 | [+7] | |
Jan 08, 2026 | United States | Series F | 6275 | [+18] |
Unicorns in Foresite Capital's Portfolio
Foresite Capital has 5 unicorns in its portfolio - Thyme Care, Mammoth, Everlywell and others. The most recent unicorn in their portfolio is Thyme Care. It became a unicorn in 2025, 2 years after Foresite Capital first invested in it.Here is a list of unicorns in Foresite Capital's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
65 | Provider of home nursing care services | 2020 | Nashville | Series D | m{dnkfc | ||
65 | Provider of molecular diagnostics platform by using CRISPR technology | 2017 | Brisbane | Series D | cbznojp | ||
60 | Provider of home-based diagnostic tests for the detection of various diseases | 2014 | Austin | Funding Raised | mtikbjq | ||
66 | Provider of end-to-end Virtual clinic offering cancer-based solutions | 2013 | Burlingame | Series E | ihmjkfv | ||
47 | Provider of osmotic pump for subcutaneous drug delivery | 1995 | Boston | Series J | dadzvap |
IPOs and Publicly Listed companies in Foresite Capital's Portfolio
80 of Foresite Capital's portfolio companies have become public. Eikon got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2026 at marketcap of $908M and Maze Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $700M.Here are Foresite Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 05, 2026 | May 05, 2021 | Series A | 9107 | |
Jan 31, 2025 | Mar 01, 2019 | Series C | 2972 | |
Jun 28, 2024 | May 05, 2021 | Series A | 4866 | |
Jun 25, 2024 | - | - | 2678 | |
Jan 25, 2024 | Aug 01, 2023 | Series E | 6216 |
Acquired companies in Foresite Capital's Portfolio
66 companies from Foresite Capital's portfolio have been acquired. The most recent acquisition were RAPT in Jan 2026 by GSK for $2.2B.Here are Foresite Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 20, 2026 | Dec 23, 2024 | Post IPO | 1909 | |
Dec 15, 2025 | Feb 27, 2018 | Series B | 5632 | |
Dec 11, 2025 | Apr 27, 2023 | Series B | 1963 | |
Jul 09, 2025 | Jul 17, 2020 | Post IPO | 1077 | |
Jun 23, 2025 | Nov 25, 2020 | Series E | 9391 |
Team profile of Foresite Capital
Foresite Capital has a team of 40 members including 12 Partners and 3 Principals located in United States. Foresite Capital's team sits on the board of 2 companies.Here is a list of top team members in Foresite Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | |||
Partner | San Francisco | |||
Partner | Denver | - | ||
Partner | San Francisco | - | ||
Partner | New York City | - | ||
Partner | San Francisco | - | ||
Partner | New York City | - | ||
Partner | Denver | - | ||
Partner | New York City | - | ||
Partner | - | - | ||
Partner | - | - | - |
Co-investors of Foresite Capital
Over the past 14 years, 867 investors have co-invested in Foresite Capital's portfolio companies. This includes funds and angels.
- Invested before Foresite Capital: HHS, Google Ventures and 339 others have invested in rounds before Foresite Capital. There are 13 companies where HHS has invested before Foresite Capital and 10 companies where Google Ventures has invested before Foresite Capital.
- Top Co-investors of Foresite Capital: 252 investors entered a company along with Foresite Capital. These include investors like Orbimed (19 companies).
- Invested after Foresite Capital: A total of 274 investors have invested in Foresite Capital's portfolio after their investments. Top Investors include Fidelity Investments (8 companies), RA Capital Management (7 companies) and Casdin Capital (7 companies).
Recent News related to Foresite Capital
•
Pinnacle raises an $89M series B for its oral peptide programsBioWorld•Mar 26, 2026•Pinnacle Medicines, LAV, Foresite Capital, Logos and 4 others
•
•
•
•
Midi Health Receives $100M Series D RoundMassinvestor•Feb 03, 2026•Join Midi, SemperVirens, Emerson Collective, Advance Venture Partners and 9 others
•
Parabilis gets $305M to conquer 'undruggable' proteins after early successEndpoints•Jan 08, 2026•Parabilis Medicines, Johnson & Johnson, Frazier Life Sciences, Rock Springs Capital and 19 others
•
Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesityEndpoints•Dec 16, 2025•Aeovian Pharmaceuticals, Hevolution, Sofinnova Investments, CTI Life Sciences Fund and 7 others
•
•
•
Foresite Capital Management VI LLC Makes New Investment in Spyre Therapeutics, Inc. $SYREMarketBeat•Nov 26, 2025•Spyre Therapeutics, Foresite Capital, Franklin Templeton Investments, and 1 other
